Treatment of chronic kidney disease (Q27694623)

chronic renal insufficiency

main subject

1 reference

Jeffrey M. Turner

1

1 reference

Carolyn Bauer

2

1 reference

Matthew K. Abramowitz

3

1 reference

Michal L. Melamed

4

1 reference

Thomas H. Hostetter

5

1 reference

language of work or name

English

0 references

publication date

February 2012

1 reference

1 reference

81

1 reference

issue

4

1 reference

page(s)

351-62

1 reference

Hyperfiltration and glomerulosclerosis

cites work

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Strategies to retard the progression of chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. The Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Intensive blood-pressure control in hypertensive chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The effect of angiotensin-converting-enzyme inhibitors on progression of advanced polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Debate: CON position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Proteinuria and phenotypic change of proximal tubular cells

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

How does proteinuria cause progressive renal damage?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Renin-angiotensin-aldosterone system and progression of renal disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Molecular mechanisms and therapeutic strategies of chronic renal injury: renoprotective effects of aldosterone blockade

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The COOPERATE trial: a letter of concern

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Controversy about COOPERATE ABPM trial data

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D).

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Aldosterone antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Aliskiren combined with losartan in type 2 diabetes and nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of intensive blood-pressure control in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

A randomized trial of furosemide vs hydrochlorothiazide in patients with chronic renal failure and hypertension

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial. The Diabetes Control and Complications (DCCT) Research Group

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications cohort

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

THE EXCRETION OF AMMONIA AND TITRATABLE ACID IN NEPHRITIS

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Control of hydrogen ion homeostasis and renal acidosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Contribution of individual superficial nephron segments to ammonium handling in chronic metabolic acidosis in the rat. Evidence for ammonia disequilibrium in the renal cortex

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of nephron reduction and dietary protein content on renal ammoniagenesis in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Pathophysiology of chronic tubulo-interstitial disease in rats. Interactions of dietary acid load, ammonia, and complement component C3.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Hypokalemic nephropathy in the rat. Role of ammonia in chronic tubular injury

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Long-term ammonium chloride or sodium bicarbonate treatment in two models of polycystic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Metabolic acidosis does not contribute to chronic renal injury in the rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Renal effects of metabolic acidosis in the normal rat

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Serum bicarbonate levels and the progression of kidney disease: a cohort study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Association of serum bicarbonate levels with mortality in patients with non-dialysis-dependent CKD.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Bicarbonate supplementation slows progression of CKD and improves nutritional status

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Acid retention accompanies reduced GFR in humans and increases plasma levels of endothelin and aldosterone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Forging forward with 10 burning questions on FGF23 in kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The role of abnormal phosphorus metabolism in the progression of chronic kidney disease and metastatic calcification

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Phosphate levels and cardiovascular disease in the general population

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Variability and risk factors for kidney disease progression and death following attainment of stage 4 CKD in a referred cohort

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Relation between alkaline phosphatase, serum phosphate, and all-cause or cardiovascular mortality

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Serum phosphate and mortality in patients with chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Chronic kidney disease progression and outcome according to serum phosphorus in mild-to-moderate kidney dysfunction

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

FGF-23 as a predictor of renal outcome in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Fibroblast Growth Factor 23 (FGF23) Predicts Progression of Chronic Kidney Disease: The Mild to Moderate Kidney Disease (MMKD) Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The pathogenesis of vascular calcification in the chronic kidney disease mineral bone disorder: the links between bone and the vasculature

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

25-hydroxyvitamin D levels, race, and the progression of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Use of vitamin D in chronic kidney disease patients

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Vitamin D receptor attenuates renal fibrosis by suppressing the renin-angiotensin system

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Parathyroid hormone, a uremic toxin

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Uric acid and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Is high serum uric acid a risk marker or a target for treatment? Examination of its independent effect in a large cohort with low cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Uric acid, CKD, and cardiovascular disease: confounders, culprits, and circles

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Elevated uric acid increases the risk for kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effect of allopurinol in chronic kidney disease progression and cardiovascular risk

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Mechanisms of renal hemodynamic regulation in response to protein feeding

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Low protein diet blunts the rise in glomerular gene expression in focal glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Lipid nephrotoxicity in chronic progressive glomerular and tubulo-interstitial disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

LDL stimulates mesangial fibronectin production and chemoattractant expression

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effect of lipoproteins on mesangial cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Renal injury of diet-induced hypercholesterolemia in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Early glomerular changes in rats with dietary-induced hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Main risk factors for nephropathy in type 2 diabetes mellitus are plasma cholesterol levels, mean blood pressure, and hyperglycemia.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of HMG-CoA reductase inhibitors (statins) on progression of kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropathy.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Protective effects of atorvastatin on chronic allograft nephropathy in rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Statins for improving renal outcomes: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Meta-analysis: the effect of statins on albuminuria

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Pirfenidone is renoprotective in diabetic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

A double-blind, randomized, controlled study of oral pirfenidone for treatment of secondary progressive multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

A pilot study in patients with established advanced liver fibrosis using pirfenidone

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Pirfenidone Slows Renal Function Decline in Patients with Focal Segmental Glomerulosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Pirfenidone for diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Bardoxolone methyl and kidney function in CKD with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The endothelin system and its antagonism in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Endothelin ET(A) receptor blockade prevents the progression of renal failure and hypertension in uraemic rats

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Protective effects of endothelin antagonists in chronic renal failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Avosentan for overt diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

A novel class of advanced glycation inhibitors ameliorates renal and cardiovascular damage in experimental rat models

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Prevention of incipient diabetic nephropathy by high-dose thiamine and benfotiamine

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

ALT-946 and aminoguanidine, inhibitors of advanced glycation, improve severe nephropathy in the diabetic transgenic (mREN-2)27 rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

LR-90 prevents dyslipidaemia and diabetic nephropathy in the Zucker diabetic fatty rat.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Association of preventive health care with atherosclerotic heart disease and mortality in CKD

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Effectiveness of a chronic kidney disease clinic in achieving K/DOQI guideline targets at initiation of dialysis--a single-centre experience

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Impact of predialysis care on clinical outcomes

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Multidisciplinary predialysis programs: quantification and limitations of their impact on patient outcomes in two Canadian settings

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Chronic kidney disease care program improves quality of pre-end-stage renal disease care and reduces medical costs

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Predialysis psychoeducational intervention and coping styles influence time to dialysis in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Primary care-based disease management of chronic kidney disease (CKD), based on estimated glomerular filtration rate (eGFR) reporting, improves patient outcomes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Impact of timing of nephrology referral and pre-ESRD care on mortality risk among new ESRD patients in the United States

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Early nephrology referral is associated with prolonged survival in hemodialysis patients even after exclusion of lead-time bias.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

The short- and long-term impact of multi-disciplinary clinics in addition to standard nephrology care on patient outcomes.

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Association between Multidisciplinary Care and Survival for Elderly Patients with Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Epithelial Notch signaling regulates interstitial fibrosis development in the kidneys of mice and humans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021

Association of trypanolytic ApoL1 variants with kidney disease in African Americans

1 reference

https://api.crossref.org/works/10.1038%2FKI.2011.380

7 January 2021